VIA
AMLX icon

Virtus Investment Advisers’s Amylyx Pharmaceuticals AMLX Stock Holding History

Virtus Investment Advisers’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Buy
20,815
+508
+3% +$7.15K 0.08% 284
2025
Q4 		$245K Buy
+20,307
New +$276K 0.07% 336

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Virtus Investment Advisers's AMLX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Amylyx Pharmaceuticals (AMLX) stake by 2.5% in Q1 2026, buying an estimated $7.15K and bringing the position to 20,815 shares worth $289K. The position accounts for 0.08% of the portfolio, ranked #284.

Virtus Investment Advisers first reported a position in AMLX in Q4 2025 and has held it in 2 quarters since. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Virtus Investment Advisers held 20,815 shares of Amylyx Pharmaceuticals worth $289K as of Q1 2026.
  • Virtus Investment Advisers bought 508 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $7.15K.
  • Amylyx Pharmaceuticals made up 0.08% of Virtus Investment Advisers's portfolio in Q1 2026, its #284 holding.
  • Virtus Investment Advisers first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.